Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Bimagrumab

A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

Eli Lilly · Phase 2 · Withdrawn · Enrollment 0

NCT06901349

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Bimagrumab Dose 1 + Tirzepatide Placebon/rn/rn/rn/r
Bimagrumab Dose 2 + Tirzepatide Placebon/rn/rn/rn/r
Tirzepatide Dose 1 + Bimagrumab Placebon/rn/rn/rn/r
Tirzepatide Dose 2 + Bimagrumab Placebon/rn/rn/rn/r
Bimagrumab Dose 2 + Tirzepatide Dose 1n/rn/rn/rn/r
Bimagrumab Dose 1 + Tirzepatide Dose 1n/rn/rn/rn/r
Bimagrumab Dose 2 + Tirzepatide Dose 2n/rn/rn/rn/r
Bimagrumab Dose 1 + Tirzepatide Dose 2n/rn/rn/rn/r
Bimagrumab Placebo + Tirzepatide Placebon/rn/rn/rn/r

Not shown

  • Bimagrumab Dose 1 + Tirzepatide Placebo: endpoint not reported
  • Bimagrumab Dose 2 + Tirzepatide Placebo: endpoint not reported
  • Tirzepatide Dose 1 + Bimagrumab Placebo: endpoint not reported
  • Tirzepatide Dose 2 + Bimagrumab Placebo: endpoint not reported
  • Bimagrumab Dose 2 + Tirzepatide Dose 1: endpoint not reported
  • Bimagrumab Dose 1 + Tirzepatide Dose 1: endpoint not reported
  • Bimagrumab Dose 2 + Tirzepatide Dose 2: endpoint not reported
  • Bimagrumab Dose 1 + Tirzepatide Dose 2: endpoint not reported
  • Bimagrumab Placebo + Tirzepatide Placebo: endpoint not reported